Evidence map›Paper›PMID 31118733›Full record

ArticleClinical, cosmetic and investigational dermatology2019

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date.

M Galluzzo, S D'Adamio, A Massaro, A Piccolo, L Bianchi, M Talamonti

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Eczematous Drug Eruptions.American journal of clinical dermatology · 2021
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

M GalluzzoDermatology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
S D'AdamioDermatology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
A MassaroDermatology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
A PiccoloDermatology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
L BianchiDermatology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
M TalamontiDermatology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).

Indexed as

anti-IL17RAatopic dermatitisbiologicsbrodalumabPASI100psoriasis

Identifiers

PMID31118733
PMCPMC6503649
OpenAlexW2943742678

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.